123 results on '"Ubilla, Begoña"'
Search Results
2. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy
3. Brief Report: Association of HLA–DRB1*01 With IgA Vasculitis (Henoch-Schönlein)
4. Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis
5. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients
6. P0443 Significant sE-Selectin Levels Reduction After 6 Months of Anti-TNF-α Therapy in Non-Diabetic Patients with Moderate-to-Severe Psoriasis
7. El tratamiento con Anti-Tnf en pacientes con psoriasis moderada-grave reduce de forma significativa la E-Selectina
8. Additional file 1: Table S1. of Incretins in patients with rheumatoid arthritis
9. Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis
10. Incretins in patients with rheumatoid arthritis
11. Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis
12. Systemic, non Cutaneous Repercussions, of Anti-TNF Therapy in Moderate to Severe Psoriatic Patients Without Cardiovascular Risk Factors a Prospective Study of 29 Patients
13. A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis
14. Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis
15. Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis
16. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis
17. P0346 Correlation Between The Metabolic Syndrom And Disease Severity In Patients With Moderate – Severe Psoriasis Treated With Adalimumab
18. Additional file 1: Table S1. of Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis)
19. Additional file 2: Table S2. of Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis)
20. Additional file 3: Table S3. of Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis)
21. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
22. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study
23. Sclerostin serum levels in patients with systemic autoimmune diseases
24. Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy
25. Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients
26. Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis)
27. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate‐to‐severe psoriasis undergoing anti‐tumor necrosis factor‐α therapy
28. Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status
29. Lack of Association betweenJAK3Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis
30. Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis
31. Osteoprotegerin CGA Haplotype Protection against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis
32. Investigation of aPON1gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis: Table 1
33. IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy
34. Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect
35. Lack of Association betweenABO,PPAP2B,ADAMST7,PIK3CG, andEDNRAand Carotid Intima-Media Thickness, Carotid Plaques, and Cardiovascular Disease in Patients with Rheumatoid Arthritis
36. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis
37. Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis
38. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients
39. Lack of Association between JAK3 Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis.
40. Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis.
41. Role of PTPN22and CSKgene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis)
42. Lack of Association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and Carotid Intima-Media Thickness, Carotid Plaques, and Cardiovascular Disease in Patients with Rheumatoid Arthritis.
43. Interferon regulatory factor 5genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis
44. Antitumour necrosis factor a treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
45. Amylin in the insulin resistance of patients with rheumatoid arthritis.
46. Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients.
47. Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
48. Interleukin 1 beta (IL1ß) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-Schönlein purpura.
49. Decreased expression of methylene tetrahydrofolate reductase (MTHFR) gene in patients with rheumatoid arthritis.
50. HLA-DRB1 association with Henoch-Schonlein purpura.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.